HRTX - Heron Therapeutics GAAP EPS of -$0.02 revenue of $34.67M
2024-05-07 08:02:30 ET
More on Heron Therapeutics
- Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
- Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
- Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
- Heron Therapeutics Q4 2023 Earnings Preview
- Seeking Alpha’s Quant Rating on Heron Therapeutics